BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TUB-040 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of TUB-040\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06303505-2785@assetmemo.bio
DTSTAMP:20261121T010131Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:TUB-040: Phase 1/2 readout est. (NCT06303505)
DESCRIPTION:TUB-040\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: FiH S
 tudy to Investigate Safety\, PK and Efficacy of the NaPi2b ADC TUB-040 in 
 Patients With PROC or r/r Adenocarcinoma NSCLC\nEstimated primary completi
 on: December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tu
 b-040#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06303505
URL:https://assetmemo.bio/drug/tub-040#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07736937-2785@assetmemo.bio
DTSTAMP:20261121T010131Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:TUB-040: Phase 1/2 readout est. (NCT07736937)
DESCRIPTION:TUB-040\, phase 1/2\, Ovarian Cancer.\nStudy: Study of TUB-040 
 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ova
 rian Cancer\nEstimated primary completion: March 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/tub-040#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07736937
URL:https://assetmemo.bio/drug/tub-040#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07806773-2785@assetmemo.bio
DTSTAMP:20261121T010131Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:TUB-040: Phase 2 readout est. (NCT07806773)
DESCRIPTION:TUB-040\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Study o
 f TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-
 small Cell Lung Cancer\nEstimated primary completion: May 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/tub-040#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07806773
URL:https://assetmemo.bio/drug/tub-040#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743541-2785@assetmemo.bio
DTSTAMP:20261121T010131Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:TUB-040: Phase 1/2 readout est. (NCT07743541)
DESCRIPTION:TUB-040\, phase 1/2.\nStudy: Study of TUB-040 in Patients With 
 Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Ther
 apy\nEstimated primary completion: September 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/tub-040#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07743541
URL:https://assetmemo.bio/drug/tub-040#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
